[ConservativeMind]

Trastuzumab deruxtecan (T-DXd) is currently available and is used for people with HER2-expressing cancers, of which prostate cancer has not generally been tested (it is tested in breast cancer cases).

It made this man’s metastatic prostate cancer currently reduce by 57% in volume, even in the brain, and he’s doing much better.

[ConservativeMind]

The “Take Charge Of Your Health” Ping List
This high volume ping list is for health articles and studies which describe something you or your doctor, when informed, may be able to immediately implement for your benefit.

Email me to get on either the “Common/Top Issues” (20 - 25% fewer pings) or “Everything” list.

[DennisR]

That is amazing. All the best to him.

[steve86]

A case report has highlighted the potential of trastuzumab deruxtecan (T-DXd) as a treatment for aggressive prostate cancer. A 60-year-old Air Force veteran with stage four metastatic prostate cancer, who had not responded to several therapies, showed significant improvement after being treated off-label with T-DXd in February 2024. This treatment, typically used for HER2-expressing cancers like breast cancer, was the first known use in prostate cancer. After four cycles, the patient experienced a 57% reduction in tumor volume and significant clinical improvement, defying previous expectations. The case underscores the importance of HER2 testing in advanced prostate cancer for identifying candidates for targeted therapies.

[Robert357]

Bump for reference: Prostate Cancer

[43north]

This is good news. Most prostate tumors are slow growing and respond well to testosterone blockade (insert Dudes for Kamala joke here). Aggressive prostate cancer is scary. That it responds to drugs used for treating breast cancer is not too surprising; breast and prostate tissues are both susceptible to hormonal influences.

[griswold3]

Starting Provenge tomorrow.
Comments?

[Mariner]

Bookmark